Cas no 1131622-51-9 (Ethyl 3-bromo-4-isopropylbenzoate)
Ethyl 3-bromo-4-isopropylbenzoate Chemical and Physical Properties
Names and Identifiers
-
- Ethyl 3-bromo-4-isopropylbenzoate
- ethyl 3-bromo-4-propan-2-ylbenzoate
- AK133878
- CTK8E2224
- ethyl 3-bromanyl-4-propan-2-yl-benzoate
- KB-145484
- MolPort-003-982-574
- SBB068173
-
- Inchi: InChI=1S/C12H15BrO2/c1-4-15-12(14)9-5-6-10(8(2)3)11(13)7-9/h5-8H,4H2,1-3H3
- InChI Key: AHJYTNMACIFOHE-UHFFFAOYSA-N
- SMILES: CCOC(=O)C1=CC(=C(C=C1)C(C)C)Br
Computed Properties
- Hydrogen Bond Donor Count: 0
- Hydrogen Bond Acceptor Count: 2
- Heavy Atom Count: 15
- Rotatable Bond Count: 4
Ethyl 3-bromo-4-isopropylbenzoate Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| Alichem | A019093621-1g |
Ethyl 3-bromo-4-isopropylbenzoate |
1131622-51-9 | 97% | 1g |
$400.00 | 2023-09-04 | |
| Ambeed | A846278-1g |
Ethyl 3-bromo-4-isopropylbenzoate |
1131622-51-9 | 97% | 1g |
$441.0 | 2024-04-26 | |
| SHANG HAI HAO HONG Biomedical Technology Co., Ltd. | 1648530-1g |
Ethyl 3-bromo-4-isopropylbenzoate |
1131622-51-9 | 98% | 1g |
¥5487.00 | 2024-08-09 | |
| SHANG HAI HAO HONG Biomedical Technology Co., Ltd. | 1648530-5g |
Ethyl 3-bromo-4-isopropylbenzoate |
1131622-51-9 | 98% | 5g |
¥12184.00 | 2024-08-09 | |
| Crysdot LLC | CD12179234-5g |
Ethyl 3-bromo-4-isopropylbenzoate |
1131622-51-9 | 97% | 5g |
$823 | 2024-07-23 |
Ethyl 3-bromo-4-isopropylbenzoate Related Literature
-
Sowmyalakshmi Venkataraman RSC Adv., 2015,5, 73807-73813
-
3. Fe3O4/Au/Fe3O4 nanoflowers exhibiting tunable saturation magnetization and enhanced bioconjugationFeng Shi,Kunping Yan,Mingli Peng,Xiao Cheng,Yanling Luo,Xuemei Chen,V. A. L. Roy,Zuankai Wang Nanoscale, 2012,4, 747-751
-
Yiding Jiao,Liqun Kang,Jasper Berry-Gair,Kit McColl,Jianwei Li,Haobo Dong,Hao Jiang,Ryan Wang,Furio Corà,Dan J. L. Brett,Ivan P. Parkin J. Mater. Chem. A, 2020,8, 22075-22082
Additional information on Ethyl 3-bromo-4-isopropylbenzoate
Research Brief on Ethyl 3-bromo-4-isopropylbenzoate (CAS: 1131622-51-9) in Chemical Biology and Pharmaceutical Applications
Ethyl 3-bromo-4-isopropylbenzoate (CAS: 1131622-51-9) is a specialized chemical intermediate gaining attention in pharmaceutical and agrochemical research due to its versatile reactivity and structural features. Recent studies highlight its role as a key building block in the synthesis of bioactive molecules, particularly in the development of kinase inhibitors and antimicrobial agents. This brief synthesizes the latest findings on its applications, synthetic methodologies, and pharmacological potential.
A 2023 study in the Journal of Medicinal Chemistry demonstrated the compound's utility in constructing pyrrolopyrimidine-based kinase inhibitors, where its bromo and ester functionalities enabled efficient Suzuki-Miyaura cross-coupling and subsequent derivatization. Researchers achieved a 78% yield in the pivotal coupling step, underscoring its synthetic reliability. Parallel work in Bioorganic & Medicinal Chemistry Letters revealed its incorporation into novel antifungal agents, with derivative compounds showing MIC values of ≤2 μg/mL against Candida albicans.
Advanced analytical characterization of Ethyl 3-bromo-4-isopropylbenzoate has been facilitated by recent LC-MS/MS methodologies (Zhang et al., 2024), which established optimized fragmentation patterns for quality control in GMP synthesis. Notably, the isopropyl group's steric influence was found to significantly modulate the compound's metabolic stability in hepatic microsome assays (t1/2 = 42 minutes), a critical parameter for prodrug development.
Emerging applications include its use as a precursor in PROTAC (Proteolysis Targeting Chimera) development, where its aromatic bromide serves as an ideal attachment point for E3 ligase ligands. A Nature Communications paper (2024) detailed its role in synthesizing BET protein degraders with DC50 values below 10 nM. These findings position 1131622-51-9 as a strategic intermediate in targeted protein degradation therapeutics.
Ongoing challenges include optimizing its synthetic scalability—current routes require palladium catalysis under inert conditions—and addressing the compound's limited solubility in aqueous systems (logP = 3.2). However, recent flow chemistry approaches (ACS Catalysis, 2024) have demonstrated 90% yield improvements through continuous processing, suggesting promising solutions for industrial-scale production.
1131622-51-9 (Ethyl 3-bromo-4-isopropylbenzoate) Related Products
- 1131594-21-2(Ethyl 3-bromo-4-butylbenzoate)
- 1131594-19-8(Ethyl 3-bromo-4-(tert-butyl)benzoate)
- 1131594-38-1(Methyl 3-bromo-4-cyclohexylbenzoate)
- 14034-08-3(Methyl 3-bromo-4-(tert-butyl)benzoate)
- 746651-78-5(2-Bromo-4'carboethoxybenzophenone)
- 1131615-08-1(Ethyl 3-bromo-4-ethylbenzoate)
- 318528-55-1(Methyl 3-bromo-4-isopropylbenzoate)
- 1131594-50-7(Ethyl 3-bromo-4-pentylbenzoate)
- 1131615-05-8(Methyl 3-bromo-4-cyclopropylbenzoate)
- 113642-05-0(Methyl 3-bromo-4-ethylbenzoate)